Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC_ [360p]

Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC_ [360p]

cancergrace

1 year
44 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.
Up Next Autoplay